FindTrial
Sign In

BFF MDI (PT009) 320/9.6 μg

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

COPDChronic Obstructive Pulmonary Disorder

Phase 3

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
CompletedNCT02497001
Pearl Therapeutics, Inc.COPD
Start: 2015-08-10End: 2018-01-05Updated: 2020-12-24
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
CompletedNCT02727660
Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disorder
Start: 2016-04-29End: 2018-04-04Updated: 2019-09-26

Related Papers

Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.
2025-11-12
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS
Respiratory Research2025-05-08
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
International Journal of COPD2024-12-012 citations
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
2024-08-053 citations
Step up to ICS/LAMA/LABA vs switch to LAMA/LABA in patients with COPD on ICS/LABA: post hoc analysis of KRONOS
2023-09-091 citations
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model.
2022-04-281 citations
Predictive modeling of COPD exacerbation rates using baseline risk factors
Therapeutic Advances in Respiratory Disease2022-01-0124 citations
S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study
2021-11-011 citations
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
2021-07-0111 citations
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
2021-06-2810 citations
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.
2021-01-2814 citations
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Therapeutic Advances in Respiratory Disease2021-01-0127 citations
EPOC: Enfoque personalizado para el tratamiento según la guía GOLD 2021
Kompass Neumología2021-01-01
Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.
2020-10-013 citations
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
ERJ Open Research2020-04-018 citations
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
2020-03-0611 citations
12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD
Pneumologie2020-02-281 citations
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study
Pneumologie2020-02-28
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
2019-12-2315 citations
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
2019-12-2314 citations

9 more papers not shown